← Tempus AI, Inc. Class A Common Stock overview

Tempus AI, Inc. Class A Common Stock vs China Mobile: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tempus AI, Inc. Class A Common Stock (TEM)

Q3 2026
▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

July 2026
▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

Latest
▲4

Tempus swings to profit, raises outlook, expands cancer data reach

  • Q2 profit and raised 2026 revenue guidance Tempus reported Q2 2026 net income of $5.64 million, a swing from a $42.84 million loss a year earlier, and lifted full-year revenue guidance to $1.60–$1.61 billion. Turning profitable and raising the outlook supports the growth story and helps justify a higher stock price.

    This is the period's clearest fundamental shift, directly improving earnings and forward revenue expectations.

  • Personalis acquisition deepens cancer recurrence testing Tempus agreed to buy Personalis for $16.25 per share, a $1.5 billion enterprise value, adding minimal residual disease testing to its oncology platform. The deal expands its cancer genomics and data offerings, though the initial market reaction was slightly negative on cost concerns.

    The acquisition is a major strategic move that broadens Tempus's technology and data moat, affecting long-term growth.

  • mRNA melanoma trial win lifts oncology data demand A phase 3 trial showed a customized mRNA melanoma treatment improved recurrence-free survival, sending Tempus shares up 39.5%. The result highlights how Tempus's data and AI tools are embedded in cutting-edge oncology, potentially boosting demand for its data and testing services.

    This event directly drove a large price move and validates Tempus's role in advanced cancer research.

  • 100,000-genome dataset expands AI research platform Tempus launched an initiative to build a 100,000 whole-genome dataset linked to clinical outcomes, with a long-term goal of one million genomes. This expands its data platform for AI-driven research, strengthening its competitive position and future data revenue potential.

    The new dataset initiative is a fresh expansion of Tempus's core data asset, supporting long-term growth.

China Mobile Limited (600941.CG)

Q3 2026
▲2▼2

China Mobile H1 Profit Falls 6.3% on Weak Telecom Revenue

  • H1 profit drops 6.3% as telecom service revenue slides China Mobile's first-half net profit fell 6.3% to 78.93 billion yuan, with operating revenue down 1.1% and telecom services revenue down 5.7%. This is the core earnings miss that pressures the stock, as the main business shrinks and profit declines.

    This is the primary new fundamental event directly hitting 600941.CG's earnings and valuation.

  • Computing and international revenue grow strongly Computing services revenue rose 14% to 52.9 billion yuan and international market revenue jumped 30.1% to 18.2 billion yuan. These new growth areas show China Mobile is diversifying beyond traditional telecom, offering a partial offset to the profit decline.

    It highlights the bright spots that could support future earnings and investor sentiment.

  • Operating cash flow jumps 37% and dividend maintained Net operating cash flow rose 37% to 114.85 billion yuan, and the company plans to distribute 25.1 yuan per 10 shares. Strong cash generation and a steady dividend provide a safety net for investors, even as reported profit falls.

    Cash flow and dividend are key supports for the stock price amid earnings weakness.

  • TRUE stake sale fear weighs on sentiment China Mobile may sell up to 1% of its 7.81% stake in Thailand's TRUE, sparking a 3.6% drop in TRUE shares. While the sale is small and for portfolio management, it signals potential capital reallocation and adds minor uncertainty for China Mobile investors.

    It is a new capital action by China Mobile that could affect its investment income and market perception.

August 2026
▲2▼2

China Mobile H1 Profit Falls 6.3% on Weak Telecom Revenue

  • H1 profit drops 6.3% as telecom service revenue slides China Mobile's first-half net profit fell 6.3% to 78.93 billion yuan, with operating revenue down 1.1% and telecom services revenue down 5.7%. This is the core earnings miss that pressures the stock, as the main business shrinks and profit declines.

    This is the primary new fundamental event directly hitting 600941.CG's earnings and valuation.

  • Computing and international revenue grow strongly Computing services revenue rose 14% to 52.9 billion yuan and international market revenue jumped 30.1% to 18.2 billion yuan. These new growth areas show China Mobile is diversifying beyond traditional telecom, offering a partial offset to the profit decline.

    It highlights the bright spots that could support future earnings and investor sentiment.

  • Operating cash flow jumps 37% and dividend maintained Net operating cash flow rose 37% to 114.85 billion yuan, and the company plans to distribute 25.1 yuan per 10 shares. Strong cash generation and a steady dividend provide a safety net for investors, even as reported profit falls.

    Cash flow and dividend are key supports for the stock price amid earnings weakness.

  • TRUE stake sale fear weighs on sentiment China Mobile may sell up to 1% of its 7.81% stake in Thailand's TRUE, sparking a 3.6% drop in TRUE shares. While the sale is small and for portfolio management, it signals potential capital reallocation and adds minor uncertainty for China Mobile investors.

    It is a new capital action by China Mobile that could affect its investment income and market perception.

Latest
▲2▼2

China Mobile H1 Profit Falls 6.3% on Weak Telecom Revenue

  • H1 profit drops 6.3% as telecom service revenue slides China Mobile's first-half net profit fell 6.3% to 78.93 billion yuan, with operating revenue down 1.1% and telecom services revenue down 5.7%. This is the core earnings miss that pressures the stock, as the main business shrinks and profit declines.

    This is the primary new fundamental event directly hitting 600941.CG's earnings and valuation.

  • Computing and international revenue grow strongly Computing services revenue rose 14% to 52.9 billion yuan and international market revenue jumped 30.1% to 18.2 billion yuan. These new growth areas show China Mobile is diversifying beyond traditional telecom, offering a partial offset to the profit decline.

    It highlights the bright spots that could support future earnings and investor sentiment.

  • Operating cash flow jumps 37% and dividend maintained Net operating cash flow rose 37% to 114.85 billion yuan, and the company plans to distribute 25.1 yuan per 10 shares. Strong cash generation and a steady dividend provide a safety net for investors, even as reported profit falls.

    Cash flow and dividend are key supports for the stock price amid earnings weakness.

  • TRUE stake sale fear weighs on sentiment China Mobile may sell up to 1% of its 7.81% stake in Thailand's TRUE, sparking a 3.6% drop in TRUE shares. While the sale is small and for portfolio management, it signals potential capital reallocation and adds minor uncertainty for China Mobile investors.

    It is a new capital action by China Mobile that could affect its investment income and market perception.

© 2026 MarketIVWhy